Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Recruiting now · Phase 2/Phase 3

Conditions studied: Non-Small Cell Lung Cancer

In brief

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Key facts

Study ID

NCT07100080

Run by

Bristol-Myers Squibb

People needed

500

Starts

2025-11-05

Expected to finish

2030-11-15

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Non-squamous NSCLC, not amenable to treatment in curative intent.
• Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
• Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
• Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).

You may not qualify if…

• Inadequate organ function and/or bone marrow reserve.
• Leptomeningeal metastases or spinal cord compression.
• Poorly controlled systemic medical conditions.
• Other protocol-defined inclusion/exclusion criteria apply.

Where it is running

• Instituto Alexander Fleming — Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina (enrolling)
• Hospital Privado Universitario de Córdoba — Córdoba, Argentina (enrolling)
• University of Virginia Health System — Charlottesville, Virginia, United States (enrolling)
• Virginia Commonwealth University (Vcu) — Richmond, Virginia, United States (enrolling)
• Shaw Cancer Center — Edwards, Colorado, United States (enrolling)
• John B Amos Cancer Center — Columbus, Georgia, United States (enrolling)
• University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
• UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building — Irvine, California, United States (enrolling)
• Piedmont Healthcare — Atlanta, Georgia, United States (enrolling)
• NYU Langone Health — New York, New York, United States (enrolling)
• Weill Cornell Medical College — New York, New York, United States (enrolling)
• Rochester General Hospital Infectious Disease — Rochester, New York, United States (enrolling)
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States (enrolling)
• Rush University Medical Center — Chicago, Illinois, United States (enrolling)
• Providence Cancer Institute Franz Clinic — Portland, Oregon, United States (enrolling)
• Providence St. Vincent Medical Center — Portland, Oregon, United States (enrolling)
• Oregon Health and Science University — Portland, Oregon, United States (enrolling)
• Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
• West Penn Allegheny Health — Pittsburgh, Pennsylvania, United States (enrolling)
• Renown Regional Medical Center — Reno, Nevada, United States (enrolling)
• Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
• Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York, United States (enrolling)
• Arthur J. E. Child Comprehensive Cancer Centre — Calgary, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.